Last reviewed · How we verify
NCT06329076
Losartan Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study
NA trial testing Losartan in Healthy in 80 participants. Currently enrolling.
1 June 2025
Quick facts
| Lead sponsor | University of Electronic Science and Technology of China |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 80 |
| Start date | 5 March 2024 |
| Primary completion | 1 June 2025 |
| Estimated completion | 30 July 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Losartan (losartan) — full drug profile →
- Placebo
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
University of Electronic Science and Technology of China
Who can join
Adults 18 to 40, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main aim of the present study is to investigate the effects of orally administered losartan on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Vasopressin and angiotensin II pathways differentially modulate human fear response dynamics to looming threats.
Han M, Dong W, Fu K, Wang J, et al · · 2026 · PMID 41734211 · DOI 10.1371/journal.pbio.3003668
Verify or expand the search:
- PubMed search for NCT06329076
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Losartan
Trials testing the same drug.
- NCT06491940 — Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan · NA · not yet recruiting
- NCT06333522 — Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty · Phase 4 · withdrawn
- NCT06150560 — A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial) · Phase 3 · recruiting
- NCT06108063 — Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan · Phase 1, PHASE2 · recruiting
- NCT06329050 — The Effects of Losartan on Attention Control: An Eye-tracking Study · NA · recruiting
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other University of Electronic Science and Technology of China trials
Trials by the same sponsor.
- NCT07416370 — Neurofeedback Training of Anterior Insula Activity Based on Unidimensional vs. Multidimensional Interoceptive Regulation · NA · enrolling by invitation
- NCT07389486 — Continuous vs. Intermittent Rt-fMRI Neurofeedback Training of the Anterior Insula · NA · recruiting
- NCT07425938 — Oxytocin's Effects on Emotional Processing and Its Acting Routes · NA · recruiting
- NCT07364084 — Real-time Neurofeedback Training of the Medial Prefrontal Cortex Based on Imagined Social Support · NA · recruiting
- NCT07367672 — The Power of Belief: Expectation-driven and Placebo Modulation of Empathic Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06329076 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Electronic Science and Technology of China
- Last refreshed: 11 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06329076.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing